First Capital Equities Limited (PSX:FCEL)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Net Income	54.06	17.8	-18.08	-79.6	90.13	-3.48
Depreciation & Amortization	0.08	0.08	0.17	0.39	0.46	0.65
Other Amortization	-	-	-	-	-	2.07
Loss (Gain) From Sale of Assets	-	-	-2.08	-	-	-0.72
Asset Writedown & Restructuring Costs	-	-	-0.06	-	-	-
Loss (Gain) From Sale of Investments	-53.16	-17.04	17.07	77.01	-94.57	-8.36
Provision & Write-off of Bad Debts	-	-	-	-	-	76.86
Other Operating Activities	6.26	6.26	-	-	-	-75.37
Change in Accounts Receivable	-	-	0.87	0.57	0.02	0.26
Change in Accounts Payable	-7.18	-6.9	0.02	1.58	2.93	2.25
Change in Other Net Operating Assets	-	-	-	-	1.01	26.97
Operating Cash Flow	0.05	0.2	-2.08	-0.05	-0.03	21.13
Sale of Property, Plant & Equipment	-	-	2.08	-	-	0.72
Sale (Purchase) of Real Estate	-	-	-	-	-	131.84
Investing Cash Flow	-	-	2.08	-	-	132.56
Long-Term Debt Repaid	-	-	-	-	-	-156.8
Total Debt Repaid	-	-	-	-	-	-156.8
Net Debt Issued (Repaid)	-	-	-	-	-	-156.8
Financing Cash Flow	-	-	-	-	-	-156.8
Net Cash Flow	0.05	0.2	-0	-0.05	-0.03	-3.11
Free Cash Flow	0.05	0.2	-2.08	-0.05	-0.03	21.13
Free Cash Flow Margin	0.10%	1.16%	-	-	-0.03%	252.73%
Free Cash Flow Per Share	-	0.00	-0.01	-	-	0.15
Cash Interest Paid	0	0	-	-	-	-
Cash Income Tax Paid	-	-6.26	-	-	-	0
Levered Free Cash Flow	28.37	-0.92	-0.81	-1.17	9.01	236.98
Unlevered Free Cash Flow	28.37	-0.92	-0.81	-1.17	9.01	236.2
Change in Net Working Capital	4.37	11.31	-11.1	-47.28	48.23	-236.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.